Back to Authors

Cardoso, M. Jorge

https://orcid.org/0000-0003-1284-2558

A5077080413 | I4405260083

Mayo Clinic

UCL Queen Square Institute of Neurology

Citations 10

IC‐P‐165: ROBUST IDENTIFICATION OF BRAIN STRUCTURES MOST DISCRIMINATIVE IN DETECTING EARLY CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_2 | Pages: No page available

10.1016/j.jalz.2018.06.2232

IC‐P‐048: SAMPLE SIZE ESTIMATES FOR SECONDARY PREVENTION STUDIES USING REGIONAL ATROPHY RATES

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_1 | Pages: No page available

10.1016/j.jalz.2018.06.2112

P2‐438: ROBUST IDENTIFICATION OF BRAIN STRUCTURES MOST DISCRIMINATIVE IN DETECTING EARLY CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_16 | Pages: No page available

10.1016/j.jalz.2018.06.1130

P1‐410: SAMPLE SIZE ESTIMATES FOR SECONDARY PREVENTION STUDIES USING REGIONAL ATROPHY RATES

Alzheimer's & Dementia | October 22, 2018 | Volume: 14 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2018.06.419

[O4–02–02]: POLY‐GP DIPEPTIDE REPEATS AND NEUROFILAMENT LIGHT CHAIN AS BIOMARKERS IN PRESYMPTOMATIC AND SYMPTOMATIC FRONTOTEMPORAL DEMENTIA CAUSED BY C9ORF72 REPEAT EXPANSIONS

Alzheimer's & Dementia | October 20, 2017 | Volume: 13 | Issue: 7S_Part_25 | Pages: No page available

10.1016/j.jalz.2017.07.425

Presymptomatic atrophy in autosomal dominant Alzheimer's disease: A serial magnetic resonance imaging study

Alzheimer's & Dementia | July 22, 2017 | Volume: 14 | Issue: 1 | Pages: 43-53

10.1016/j.jalz.2017.06.2268 | PMID 28738187

Abstract Introduction Identifying at what point atrophy rates first change in Alzheimer's disease is important for informing design of presymptomatic trials. Methods Serial T1‐weighted magnetic resonance imaging scans of 94 participants (28 noncarriers, 66 carriers) from the Dominantly Inherited Alzheimer Network were used to measure brain, ventricular, and hippocampal atrophy rates. For each structure, nonlinear mixed‐effects models estimated the change‐points when atrophy rates deviate from normal and the rates of change before and after this point. Results Atrophy increased after the change‐point, which occurred 1–1.5 years (assuming a single step change in atrophy rate) or 3–8 years (assuming gradual acceleration of atrophy) before expected symptom onset. At expected symptom onset, estimated atrophy rates were at least 3.6 times than those before the change‐point. Discussion Atrophy rates are pathologically increased up to seven years before “expected onset”. During this period, atrophy rates may be useful for inclusion and tracking of disease progression.
P1‐025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI)

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_8 | Pages: No page available

10.1016/j.jalz.2016.06.772

IC‐P‐106: LONGITUDINAL RATES OF ATROPHY IN FAMILIAL ALZHEIMER'S DISEASE

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_6 | Pages: No page available

10.1016/j.jalz.2014.05.112

P3–134: Dissociating volume and intensity differences in familial Alzheimer's disease

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2013.05.1205

P2‐226: Cross‐sectional cerebral volumetric differences and associations with estimated time to age‐at‐onset in familial Alzheimer's disease: Findings from the DIAN study

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_9 | Pages: No page available

10.1016/j.jalz.2012.05.933